Furthermore, concurrent treatment with LV has been shown to enhance the antitumor activity of tegafur–uracil (UFT) against 5FU-resistant colorectal tumor xenografts with increased TS expression [15], suggesting that 5FU-based therapy including LV may overcome resistance to 5FU caused by increased TS expression. The gene discussed is TYMS; the disease is colorectal neoplasm.